查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1632662

阿片类药物使用障碍市场规模、份额、趋势分析报告：按药物、给药途径、分销管道、地区、细分市场预测，2025-2030 年

Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug (Naltrexone, Buprenorphine, Methadone), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

阿片类药物使用障碍市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球阿片类药物使用障碍市场规模预计将达到102.4亿美元，2025年至2030年复合年增长率为11.15%。

阿片类药物流行率的上升和政府应对危机的倡议不断增加预计将推动市场成长。此外，新产品商业化的增加预计将进一步推动成长。 2018年，美国大约有290万15岁以上的人患有这种疾病。 2016年，全国药物使用与健康美国（NSDUH）发现，美国约有1,150万人在上一年滥用处方鸦片类药物，超过200万人对处方药上瘾。

据CDC称，每天约有130名美国死于阿片类药物过量摄取，美国政府已将其列为突发公共卫生事件。对于想要克服毒瘾的患者来说，坚持药物辅助治疗（MAT）可以减少戒断症状并将死亡风险降低一半。美国FDA核准了三种 MAT 选项：Buprenornhine、美沙酮和纳曲酮。每日口服Buprenornhine是标准治疗方法。

近年来采取了多项措施来应对鸦片类药物危机。例如，2016 年，CDC 发布了针对慢性疼痛处方这些药物的临床实践指南，并于 2015 年采用了新的美国成瘾协会实践指南，以提高护理标准。此外，2016 年，美国FDA 宣布计划全面改革其防止滥用的鸦片类药物法规，加强安全标籤，并重新考虑使用的风险效益范式。

阿片类药物使用疾患市场报告亮点

  • Buprenornhine作为阿片类部分致效剂的有效双重作用而引领市场，2024年占全球销售额的59.58%。
  • 注射剂细分市场占据主导地位，2024 年占全球销售额的 59.26%。 Vivitrol（纳曲酮）和 Subrocade（Buprenornhine）等缓释性注射剂可长时间提供稳定的药物输送，提高用药依从性并降低復发风险。
  • 医院药局在管理复杂、严重病例中发挥至关重要的作用，预计到2024年，医院药局的市场占有率将达到47.90%，并占据市场主导地位。
  • 由于几个关键因素，北美阿片类药物使用障碍市场在 2024 年占据 68.98% 的份额。该地区 OUD 患病率最高，推动了对治疗解决方案的巨大需求。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章阿片类药物使用疾患市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 阿片类药物使用疾患市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 价格分析
  • 管道分析
  • 行为治疗的质性分析

第四章阿片类药物使用疾患市场分析（依药物）

  • 2024年及2030年药品市场占有率
  • 细分仪表板
  • 按药物前景分類的全球阿片类药物使用障碍市场
  • 2018-2030年市场规模、预测及趋势分析
    • Buprenornhine
    • 美沙酮
    • 纳曲酮
    • 其他的

第五章阿片类药物使用疾患市场分析（依给药途径）

  • 阿片类药物使用障碍：给药途径变化分析
  • 阿片类药物使用障碍市场分析，依给药途径分類的市场
    • 口服给药
    • 注射给药
    • 其他的

第六章阿片类药物使用疾患市场分析（依通路）

  • 阿片类药物使用疾患：通路变化分析
  • 阿片类药物使用障碍市场分析（依分销通路市场）
    • 医院药房
    • 零售药房
    • 其他的

第七章阿片类药物使用障碍市场：按药物、给药途径和分销管道分類的区域估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场简介
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • Key customers
    • Key company market share analysis, 2024
    • Indivior PLC
    • Teva Pharmaceutical Industries, Ltd.
    • Pfizer, Inc.
    • BioDelivery Sciences International, Inc.（a part of Collegium Pharmaceutical, Inc.）
    • Genentech, Inc.（Roche）
    • Alkermes.
    • Orexo US Inc.（subsidiary of Orexo AB）
    • Titan Pharmaceuticals, Inc.
    • Omeros Corporation
    • Camurus AB
    • Hikma Pharmaceuticals PLC
Product Code: GVR-3-68038-353-9

Opioid Use Disorder Market Growth & Trends:

The global opioid use disorder market size is expected to reach USD 10.24 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 11.15% from 2025 to 2030. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

According to the CDC, around 130 Americans die every day due to the opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

Opioid Use Disorder Market Report Highlights:

  • Buprenorphine led the market and accounted for 59.58% of the global revenue in 2024 due to its effective dual action as a partial opioid agonist, which helps alleviate withdrawal symptoms and cravings while minimizing euphoria and misuse risk.
  • The injectable segment dominated the market and accounted for 59.26% of the global revenue in 2024. Extended release injectables, like Vivitrol (naltrexone) and Sublocade (buprenorphine), offer prolonged, steady drug delivery, improving adherence and reducing the risk of relapse.
  • Hospital pharmacies dominated the market with a market share of 47.90% in 2024 due to their integral role in managing complex and severe cases.
  • North America opioid use disorder market accounted for 68.98% share in 2024 due to several key factors. The region has the highest prevalence of OUD, which drives significant demand for treatment solutions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary Distribution Channels
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Distribution Channels
  • 1.9. List of Primary Distribution Channels
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug
    • 2.2.2. Route of Administration
    • 2.2.3. Distribution Channel
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Opioid Use Disorder Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising opioid epidemic
      • 3.2.1.2. Growing government initiatives to combat the crisis
      • 3.2.1.3. Growing awareness of opioid use disorder (OUD)
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Adverse effects associated to drug used for opioid treatment
      • 3.2.2.2. Complex reimbursement structure
  • 3.3. Opioid Use Disorder Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pricing Analysis
  • 3.5. Pipeline Analysis
  • 3.6. Qualitative analysis about Behavioral Therapies

Chapter 4. Opioid Use Disorder Market Analysis, by Drug, 2018-2030 (USD Million)

  • 4.1. Drug Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Opioid Use Disorder Market by Drug Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Buprenorphine
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Belbuca
        • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Suboxone
        • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Zubsolv
        • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
        • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Methadone
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Naltrexone
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Opioid Use Disorder Market Analysis, by Route of Administration, 2018-2030 (USD Million)

  • 5.1. Opioid Use Disorder: Route of Administration Movement Analysis
  • 5.2. Opioid Use Disorder Market Analysis, by Route of Administration Market (USD Million)
    • 5.2.1. Oral Administration
      • 5.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
    • 5.2.2. Injectable Administration
      • 5.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
    • 5.2.3. Others
      • 5.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 6. Opioid Use Disorder Market Analysis, by Distribution Channel, 2018-2030 (USD Million)

  • 6.1. Opioid Use Disorder: Distribution Channel Movement Analysis
  • 6.2. Opioid Use Disorder Market Analysis, by Distribution Channel Market (USD Million)
    • 6.2.1. Hospital Pharmacies
      • 6.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
    • 6.2.2. Retail Pharmacies
      • 6.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
    • 6.2.3. Others
      • 6.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 7. Opioid Use Disorder Market: Regional Estimates and Trend Analysis by Drug, by Route of Administration, by Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Indivior PLC
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Drug benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Teva Pharmaceutical Industries, Ltd.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Drug benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Pfizer, Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Drug benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. BioDelivery Sciences International, Inc. (a part of Collegium Pharmaceutical, Inc.)
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Drug benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Genentech, Inc. (Roche)
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Drug benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Alkermes.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Drug benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Orexo US Inc. (subsidiary of Orexo AB)
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Drug benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Titan Pharmaceuticals, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Drug benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Omeros Corporation
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Drug benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Camurus AB
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Drug benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Hikma Pharmaceuticals PLC
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Drug benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 4 Global opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 North America opioid use disorder market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 8 North America opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 North America opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 11 U.S. opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 Canada opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Canada opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Canada opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 17 Mexico opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Europe opioid use disorder market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 21 Europe opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Europe opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 23 UK opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 24 UK opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 25 UK opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Germany opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 27 Germany opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 Germany opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 France opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 30 France opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 France opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Italy opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 33 Italy opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34 Italy opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 35 Spain opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 36 Spain opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Spain opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 Norway opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 39 Norway opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Norway opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 42 Sweden opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Sweden opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Denmark opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 45 Denmark opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 Denmark opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific opioid use disorder market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 51 Japan opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 52 Japan opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53 Japan opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 China opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 55 China opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 China opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 India opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 58 India opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 India opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 60 Australia opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 61 Australia opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 62 Australia opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 South Korea opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 64 South Korea opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 South Korea opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 67 Thailand opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Thailand opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America opioid use disorder market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 71 Latin America opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 Latin America opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 74 Brazil opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 75 Brazil opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 77 Argentina opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 Argentina opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa opioid use disorder market, by country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 84 South Africa opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 South Africa opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 89 UAE opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 90 UAE opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 91 UAE opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 93 Kuwait opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 94 Kuwait opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Opioid use disorder market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Drug and route of administration segment snapshot
  • Fig. 11 Distribution channel snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Global Pharmaceutical Market (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Opioid use disorder: Drug outlook and key takeaways
  • Fig. 18 Opioid use disorder market: Drug market movement analysis
  • Fig. 19 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 BELBUCA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Sublocade market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Suboxone market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Zubsolv market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Other Buprenorphine products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Methadone market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Opioid use disorder: Route of administration outlook and key takeaways
  • Fig. 29 Opioid use disorder market: Route of administration market movement analysis
  • Fig. 30 Oral administration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Injectable administration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Opioid use disorder: Distribution channel outlook and key takeaways
  • Fig. 34 Opioid use disorder market: Distribution channel market movement analysis
  • Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Opioid use disorder market revenue, by region, 2023 & 2030, USD Million
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Canada opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Mexico opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Europe opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 UK opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Germany opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 France opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Spain opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Italy opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Denmark opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Sweden opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Norway opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Rest of Europe opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Japan opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 China opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 China regulatory details
  • Fig. 71 India opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Australia opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Thailand opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 South Korea opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Rest of Asia Pacific opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Brazil opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Brazil regulation details
  • Fig. 83 Key country dynamics
  • Fig. 84 Argentina opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina regulatory framework
  • Fig. 86 Rest of Latin America opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 South Africa opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Saudi Arabia opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 UAE opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Kuwait opioid use disorder market estimates and forecasts, 2018
  • Fig. 95 Rest of MEA opioid use disorder market estimates and forecasts,
  • Fig. 96 Company/competition categorization
  • Fig. 97 Company market share analysis, 2024
  • Fig. 98 Strategy mapping